TRIM9 and central nervous system cancer: In addition, auto-antibodies against TRIM9/SPRING and TRIM67/TNL have been described as a potential high-risk paraneoplastic biomarker [113], and TRIM67/TNL is associated with higher cell motility and reduced cell adherence in glioma cells.